Evaluating response to disease-modifying therapy in relapsing multiple sclerosis

Expert Review of Neurotherapeutics
Mark S Freedman, Mohammad Abdoli

Abstract

Despite the broadening range of available treatments, the response of multiple sclerosis patients to disease-modifying therapies remains quite heterogeneous, thus a scheme is required in order to flag individuals achieving a suboptimal treatment response, so that they may switch to a different, possibly more effective disease-modifying therapy. There are several treatment outcomes that can be defined as surrogate markers for continued treatment efficacy and can be used for optimizing disease-modifying therapy. As no single marker is validated, we must make use of all available potential surrogates to help predict the future course of the disease. Only by putting all of the outcome measures together can a true picture be derived that will indicate an optimal response to treatment.

References

Mar 10, 1990·BMJ : British Medical Journal·A J ThompsonW I McDonald
Aug 1, 1988·Brain : a Journal of Neurology·D H MillerW I McDonald
Jan 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·M FilippiG Comi
Feb 1, 1993·Brain : a Journal of Neurology·B Runmarker, O Andersen
Jan 1, 1995·Duodecim; lääketieteellinen aikakauskirja·M PaneliusJ Ruutiainen
Jul 1, 1996·Journal of Magnetic Resonance Imaging : JMRI·C GasperiniW I McDonald
Dec 1, 1996·Brain : a Journal of Neurology·N A LosseffA J Thompson
Mar 1, 1997·Journal of Neurology, Neurosurgery, and Psychiatry·T KoudriavtsevaC Pozzilli
Apr 1, 1997·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·M FilippiG Comi
Apr 29, 1998·Brain : a Journal of Neurology·D H MillerH F McFarland
Jul 30, 1999·Journal of Neuroimmunology·J H Simon
Jun 24, 2000·Journal of the Neurological Sciences·M FilippiG Comi
Aug 30, 2000·Multiple Sclerosis : Clinical and Laboratory Research·M KaufmanJ Norton
Nov 18, 2000·The New England Journal of Medicine·C ConfavreuxP Adeleine
Feb 24, 2001·Multiple Sclerosis : Clinical and Laboratory Research·R A RudickJ Simon
Jun 16, 2001·Brain : a Journal of Neurology·F BarkhofUNKNOWN European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis
Aug 28, 2001·Brain : a Journal of Neurology·M RovarisUNKNOWN European/Canadian Glatiramer Acetate Study Group
Aug 29, 2001·Neurology·M FilippiUNKNOWN Eurpoean/Canadian Glatiramer Acetate Study Group
Sep 6, 2001·Journal of the Neurological Sciences·R BergamaschiV Cosi
Jan 5, 2002·Neurology·P D MolyneuxUNKNOWN European Study Group on Interferon Beta-1b in Secondary Progressive MS

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses
Christina CaonNancy Baxter
Current Neurology and Neuroscience Reports
Vijayshree Yadav, Dennis Bourdette
Journal of Clinical Pharmacology
J W Blue, W A Colburn
© 2021 Meta ULC. All rights reserved